Erectile Dysfunction and Dyslipidemia: Relevance and Role of Phosphodiesterase Type-5 Inhibitors and Statins
Version of Record online: 5 MAR 2008
© 2008 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 5, Issue 5, pages 1066–1078, May 2008
How to Cite
Miner, M. and Billups, K. L. (2008), Erectile Dysfunction and Dyslipidemia: Relevance and Role of Phosphodiesterase Type-5 Inhibitors and Statins. Journal of Sexual Medicine, 5: 1066–1078. doi: 10.1111/j.1743-6109.2008.00783.x
- Issue online: 5 MAR 2008
- Version of Record online: 5 MAR 2008
- Erectile Dysfunction (ED);
- Phosphodiesterase type-5 (PDE5) Inhibitors;
- Cardiovascular Disease (CVD);
Introduction. There is a close link between hyperlipidemia/dyslipidemia and erectile dysfunction (ED), with endothelial dysfunction as a common mechanism. Both ED and hyperlipidemia/dyslipidemia are rising in prevalence with mounting evidence that these conditions are harbingers of cardiovascular disease.
Aim. This review was conducted to provide an update on the epidemiology and oral therapy of both dyslipidemia and ED, the connection between these two conditions, and clinical outcomes relating to the use of statins and phosphodiesterase type-5 (PDE5) inhibitors in men with ED who have associated dyslipidemia.
Methods. A systematic search was performed of MEDLINE and EMBASE research databases to obtain articles pertaining to the epidemiology, mechanism, and clinical outcomes of statins and PDE5 inhibitors in men with ED and associated dyslipidemia.
Main Outcome Measures. The clinical and preclinical studies related to ED and dyslipidemia are analyzed and their findings are assessed and summarized.
Results. Hyperlipidemia/Dyslipidemia constitute a vascular risk factor having a considerable impact on erectile function. Furthermore, the role of endothelial dysfunction in the pathophysiology of both ED and dyslipidemia is paramount suggesting the importance of comanaging these conditions. Therefore, hyperlipidemia/dyslipidemia when present in patients with ED should prompt management with diet/exercise as well as appropriate pharmacotherapy. With ED being often associated with comorbidities, the use of concomitant pharmacotherapies enhances opportunities for managing the overall global cardiometabolic risk. Newer studies assessing the effect of PDE5 inhibitors in men with dyslipidemia will shed more light on the clinical profile of these agents when used in this patient population.
Conclusions. While dyslipidemia and ED are important concerns for clinicians, there exists a gap that needs to be closed between the number of individuals who have either or both conditions and those who are receiving appropriate therapy based on evidence and patient-driven goals regarding clinical outcomes. Miner M, and Billups KL. Erectile dysfunction and dyslipidemia: Relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med 2008;5:1066–1078.